<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683358</url>
  </required_header>
  <id_info>
    <org_study_id>IMSUT-PPKVEGFR12402</org_study_id>
    <nct_id>NCT00683358</nct_id>
  </id_info>
  <brief_title>Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase Ⅰ/Ⅱ Trial of Human Leukocyte Antigen (HLA)-A*2402-Restricted Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Derived Peptide Vaccination Combined With Gemcitabine for Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokyo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tokyo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility and efficacy of combined modality intervention using chemotherapeutic agent
      gemcitabine with anti-angiogenic peptide vaccination targeting VRGFR1 should be determined in
      case of advanced/inoperable or therapy-resistant pancreatic cancer patients.

      Gemcitabine 1,000mg/m2 BSA will be administered on day1, day8, day15, day29, day36, day43,
      respectively.

      HLA-A*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084; SYGVLLWEI) emulsified with
      Montanide ISA51 will be subcutaneously injected twice weekly for 8weeks (total 16 doses).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HLA-A*2402-restricted cytotoxic T lymphocyte (CTL) clones were obtained from healthy
      volunteer donor peripheral blood.

      These CTL clones showed potent cytotoxicities selectively against VEGFR1-expressing target
      cells in HLA-class I-restricted manner.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Anticipated">April 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PhaseⅠ; safety (NCI CTCAE v.3) PhaseⅡ；time to progression (RECIST)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response (ELISPOT, Perforin/FoxP3 FACS, in vitro CTL assay etc.)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor regression(Imaging study, tumor marker, etc.)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreas Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VEGFR1-A24-1084 (SYGVLLWEI)</intervention_name>
    <description>HLA-A*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084) 1mg emulsified with Montanide ISA51 will be subcutaneously injected 2 times weekly for total 16doses concurrently with conventional dose of gemcitabine 1,000mg/m2 BSA on 1st, 2nd, 3rd, 5th, 6th, 7th weeks for advanced/inoperable pancreatic cancer patients.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>HLA-A*2402</other_name>
    <other_name>advanced pancreatic cancer</other_name>
    <other_name>VEGFR1</other_name>
    <other_name>VEGFR1-A24-1084</other_name>
    <other_name>SYGVLLWEI</other_name>
    <other_name>IFA</other_name>
    <other_name>Montanide ISA51</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heterozygote or homozygote of HLA-A*2402 allele

          -  Inoperable or recurrent pancreatic cancer with or without any prior therapy

          -  Difficult to continue the prior therapy due to treatment-related toxicities

          -  ECOG performance status 0-2

          -  Evaluable primary or metastatic lesion with RECIST criteria

          -  Clearance period from prior therapy more than 4 weeks

          -  Life expectancy more than 3 months

          -  Laboratory values as follows 2,000/μL&lt;WBC&lt;15,000/μL Platelet count&gt;100,000/μL
             AST&lt;150IU/L ALT&lt;150IU/L Total bilirubin&lt;3.0mg/dl Serum creatinine&lt;3.0mg/dl

        Exclusion Criteria:

          -  Pregnancy (refusal or inability to use effective contraceptives)

          -  Breastfeeding

          -  Active or uncontrolled infection

          -  Systemic use of corticosteroids or immunosuppressants

          -  Uncontrollable brain metastasis and/or meningeal infiltration

          -  Unhealed external wound

          -  Possibilities of complicated paralytic ileus or interstitial pneumonitis

          -  Decision of not eligible determined by principal investigator or attending doctor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naohide Yamashita, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Director, Research Hospital, Institute of Medical Science, Tokyo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Hospital, The Institute of Medical Science, The University of Tokyo</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-8639</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.transrec.jp/english/index.html</url>
  </link>
  <reference>
    <citation>Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9.</citation>
    <PMID>17020992</PMID>
  </reference>
  <reference>
    <citation>Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, Yamasaki T, Enomoto M, Nakaoka T, Nakamura T, Maekawa T, Yamamoto A, Shimada S, Saida T, Kawakami Y, Asano S, Tani K, Takahashi TA, Yamashita N. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res. 2003 Oct;13(5):521-30.</citation>
    <PMID>14512794</PMID>
  </reference>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2008</study_first_posted>
  <last_update_submitted>May 6, 2009</last_update_submitted>
  <last_update_submitted_qc>May 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Naohide Yamashita MD, PhD</name_title>
    <organization>Research Hospital, Institute of Medical Science, The University of Tokyo</organization>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>pancreas</keyword>
  <keyword>advanced</keyword>
  <keyword>peptide</keyword>
  <keyword>vaccination</keyword>
  <keyword>VEGFR1</keyword>
  <keyword>HLA</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>IFA</keyword>
  <keyword>Cancer of Pancreas</keyword>
  <keyword>Neoplasms, Pancreatic</keyword>
  <keyword>Pancreas Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 9, 2009</submitted>
    <returned>July 24, 2009</returned>
    <submitted>October 23, 2009</submitted>
    <returned>November 23, 2009</returned>
    <submitted>July 23, 2010</submitted>
    <returned>August 19, 2010</returned>
    <submitted>October 19, 2010</submitted>
    <returned>November 17, 2010</returned>
    <submitted>July 19, 2011</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>July 20, 2011</submitted>
    <returned>August 15, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

